JP2009501797A - 増強された眼神経保護／神経刺激 - Google Patents

増強された眼神経保護／神経刺激 Download PDF

Info

Publication number
JP2009501797A
JP2009501797A JP2008522862A JP2008522862A JP2009501797A JP 2009501797 A JP2009501797 A JP 2009501797A JP 2008522862 A JP2008522862 A JP 2008522862A JP 2008522862 A JP2008522862 A JP 2008522862A JP 2009501797 A JP2009501797 A JP 2009501797A
Authority
JP
Japan
Prior art keywords
factor
patient
macrolide
neuroprotective
neurostimulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008522862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009501797A5 (OSRAM
Inventor
ゴーラム・エー・ペイマン
Original Assignee
ミヌ・エル・エル・シー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミヌ・エル・エル・シー filed Critical ミヌ・エル・エル・シー
Priority claimed from PCT/US2006/027713 external-priority patent/WO2007011880A2/en
Publication of JP2009501797A publication Critical patent/JP2009501797A/ja
Publication of JP2009501797A5 publication Critical patent/JP2009501797A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Prostheses (AREA)
JP2008522862A 2005-07-18 2006-07-18 増強された眼神経保護／神経刺激 Pending JP2009501797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/183,355 US20070014760A1 (en) 2005-07-18 2005-07-18 Enhanced recovery following ocular surgery
US11/263,737 US20070015697A1 (en) 2005-07-18 2005-11-01 Enhanced ocular neuroprotection and neurostimulation
PCT/US2006/027713 WO2007011880A2 (en) 2005-07-18 2006-07-18 Enhanced ocular neuroprotection/neurostimulation

Publications (2)

Publication Number Publication Date
JP2009501797A true JP2009501797A (ja) 2009-01-22
JP2009501797A5 JP2009501797A5 (OSRAM) 2009-09-03

Family

ID=37661858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522862A Pending JP2009501797A (ja) 2005-07-18 2006-07-18 増強された眼神経保護／神経刺激

Country Status (8)

Country Link
US (4) US20070014760A1 (OSRAM)
EP (1) EP2074994A1 (OSRAM)
JP (1) JP2009501797A (OSRAM)
AT (1) ATE429914T1 (OSRAM)
BR (1) BRPI0612859A2 (OSRAM)
DE (1) DE602006006575D1 (OSRAM)
DK (1) DK1904056T3 (OSRAM)
ES (1) ES2326550T3 (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524431A (ja) * 2012-07-27 2015-08-24 クロンズ ホールディングズ カンパニー リミテッドＣｕｒｏｎｚ Ｈｏｌｄｉｎｇｓ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 視神経損傷、眼虚血または眼の再灌流傷害を治療する方法
JP2016026229A (ja) * 2009-11-16 2016-02-12 エイチエムエフアールエイ ハンガリー リミテッド ライアビリティー カンパニーＨｍｆｒａ Ｈｕｎｇａｒｙ Ｌｉｍｉｔｅｄ Ｌｉａｂｉｌｉｔｙ Ｃｏｍｐａｎｙ Ｂｄｎｆ（脳由来神経栄養因子）をベースとする眼科用製剤およびそれらの使用
JP2020523416A (ja) * 2017-06-15 2020-08-06 アジエンダ・オスペダリエロ−ウニベルシタリア・ディ・ボローニャ・ポリクリニコ・エス・オルソラ−マルピーギＡｚｉｅｎｄａ Ｏｓｐｅｄａｌｉｅｒｏ−Ｕｎｉｖｅｒｓｉｔａｒｉａ Ｄｉ Ｂｏｌｏｇｎａ Ｐｏｌｉｃｌｉｎｉｃｏ Ｓ．Ｏｒｓｏｌａ−Ｍａｌｐｉｇｈｉ 神経変性眼科学的病状の治療に使用する血清
CN113301915A (zh) * 2019-01-04 2021-08-24 加利福尼亚大学董事会 用于促进眼中的血管生成的组合物和方法
JP2022540291A (ja) * 2019-05-16 2022-09-15 沈陽福洋医薬科技有限公司 線維化を予防、緩和及び／又は治療するための薬物、組成製品及びその応用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505932A (ja) * 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
WO2006086750A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CN101443004B (zh) * 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070237722A1 (en) * 2006-03-28 2007-10-11 Peyman Gholam A Neural conduit agent dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
CN102215682A (zh) * 2008-03-11 2011-10-12 万能医药公司 大环内酯化合物及它们的使用方法
CN105380947A (zh) * 2008-03-11 2016-03-09 万能医药公司 大环内酯化合物及它们的使用方法
US9943401B2 (en) * 2008-04-04 2018-04-17 Eugene de Juan, Jr. Therapeutic device for pain management and vision
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
WO2011050327A1 (en) * 2009-10-23 2011-04-28 Forsight Labs Llc Corneal denervation for treatment of ocular pain
US9498385B2 (en) 2009-10-23 2016-11-22 Nexisvision, Inc. Conformable therapeutic shield for vision and pain
US8591025B1 (en) 2012-09-11 2013-11-26 Nexisvision, Inc. Eye covering and refractive correction methods for LASIK and other applications
AU2011323743B2 (en) 2010-10-25 2016-01-28 Nexisvision, Inc. Methods and apparatus to identify eye coverings for vision
US8678584B2 (en) 2012-04-20 2014-03-25 Nexisvision, Inc. Contact lenses for refractive correction
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
AU2012249773A1 (en) 2011-04-28 2013-11-07 Nexisvision, Inc. Eye covering and refractive correction methods and apparatus having improved tear flow, comfort, and/or applicability
WO2014210186A2 (en) 2013-06-26 2014-12-31 Nexisvision, Inc. Contact lenses for refractive correction
ITRM20110233A1 (it) * 2011-05-10 2012-11-11 Univ Calabria Azitromicina, suoi sali o solvati farmaceuticamente accettabili per l?uso come neuroprotettori.
WO2013011511A1 (en) 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
RU2494707C2 (ru) * 2011-12-23 2013-10-10 Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") Способ лечения открытоугольной глаукомы
HK1208268A1 (en) 2012-04-20 2016-02-26 内希斯视觉股份有限公司 Contact lenses for refractive correction
US9465233B2 (en) 2012-04-20 2016-10-11 Nexisvision, Inc. Bimodular contact lenses
US9341864B2 (en) 2013-11-15 2016-05-17 Nexisvision, Inc. Contact lenses having a reinforcing scaffold
WO2015116559A1 (en) 2014-01-29 2015-08-06 Nexisvision, Inc. Multifocal bimodulus contact lenses
US20210275020A1 (en) * 2016-07-18 2021-09-09 Baylor College Of Medicine Non-contact air esthesiometer
WO2021186041A1 (en) * 2020-03-19 2021-09-23 Universität Rostock Josamycin for use in prevention and treatment of fibrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011813A2 (en) * 2003-07-30 2005-02-10 Minu, L.L.C. Treatment of ocular disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US634693A (en) * 1899-02-23 1899-10-10 Carnegie Steel Company Ltd Clamp for poles or columns.
FR900520A (fr) 1943-12-13 1945-07-02 Nouveau système de trusquin
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
KR920003601B1 (ko) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US4946931A (en) * 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
IE66485B1 (en) * 1989-07-05 1996-01-10 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5788687A (en) * 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5457182A (en) * 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US6179817B1 (en) * 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
WO1997029160A1 (en) * 1996-02-09 1997-08-14 Surface Solutions Laboratories, Inc. Water-based hydrophilic coating compositions and articles prepared therefrom
EP1640003A2 (en) * 1996-02-13 2006-03-29 G.D. SEARLE & CO. Compositions comprising a Cyclooxygenase-2 Inhibitor and a Leukotriene B4 receptor antagonist
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
KR100514277B1 (ko) * 1996-09-13 2005-09-13 유겐가이샤 사이센딴이가꾸겡꾸쇼 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US20030181692A1 (en) * 1997-06-06 2003-09-25 Jian Ni 207 human secreted proteins
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
WO1999051215A2 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
US6218423B1 (en) * 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
WO2001010421A1 (en) * 1999-08-06 2001-02-15 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
DE60100866T2 (de) * 2000-04-07 2004-07-29 Laboratoire Medidom S.A. Cyklosporin, Hyaluronsäure und Polysorbate enthaltenes Augenarzneimittel
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US6440942B1 (en) * 2000-12-22 2002-08-27 Enanta Pharmaceuticals, Inc. 14-membered macrolides derived from leucomycins
US6462026B1 (en) * 2001-02-16 2002-10-08 Enanta Pharmaceuticals, Inc. Bicyclic leucomycins
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6436906B1 (en) * 2001-04-02 2002-08-20 Enanta Pharmaceuticals, Inc. 9-amino-14-membered macrolides derived from leucomycins
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20040162315A1 (en) * 2002-07-23 2004-08-19 Hellberg Mark R. Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US10575605B2 (en) 2010-03-09 2020-03-03 F.D. Worldwide Merchandise Group, Inc. Jewelry stones set with prongs and invisible settings
US10328305B1 (en) 2016-06-06 2019-06-25 Joseph D Maresh Exercise machine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011813A2 (en) * 2003-07-30 2005-02-10 Minu, L.L.C. Treatment of ocular disease

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016026229A (ja) * 2009-11-16 2016-02-12 エイチエムエフアールエイ ハンガリー リミテッド ライアビリティー カンパニーＨｍｆｒａ Ｈｕｎｇａｒｙ Ｌｉｍｉｔｅｄ Ｌｉａｂｉｌｉｔｙ Ｃｏｍｐａｎｙ Ｂｄｎｆ（脳由来神経栄養因子）をベースとする眼科用製剤およびそれらの使用
JP2015524431A (ja) * 2012-07-27 2015-08-24 クロンズ ホールディングズ カンパニー リミテッドＣｕｒｏｎｚ Ｈｏｌｄｉｎｇｓ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 視神経損傷、眼虚血または眼の再灌流傷害を治療する方法
JP2020523416A (ja) * 2017-06-15 2020-08-06 アジエンダ・オスペダリエロ−ウニベルシタリア・ディ・ボローニャ・ポリクリニコ・エス・オルソラ−マルピーギＡｚｉｅｎｄａ Ｏｓｐｅｄａｌｉｅｒｏ−Ｕｎｉｖｅｒｓｉｔａｒｉａ Ｄｉ Ｂｏｌｏｇｎａ Ｐｏｌｉｃｌｉｎｉｃｏ Ｓ．Ｏｒｓｏｌａ−Ｍａｌｐｉｇｈｉ 神経変性眼科学的病状の治療に使用する血清
CN113301915A (zh) * 2019-01-04 2021-08-24 加利福尼亚大学董事会 用于促进眼中的血管生成的组合物和方法
JP2022540291A (ja) * 2019-05-16 2022-09-15 沈陽福洋医薬科技有限公司 線維化を予防、緩和及び／又は治療するための薬物、組成製品及びその応用

Also Published As

Publication number Publication date
US20080102101A1 (en) 2008-05-01
US20070014760A1 (en) 2007-01-18
DE602006006575D1 (de) 2009-06-10
ES2326550T3 (es) 2009-10-14
EP2074994A1 (en) 2009-07-01
BRPI0612859A2 (pt) 2010-11-30
US20090143282A1 (en) 2009-06-04
DK1904056T3 (da) 2009-08-10
ATE429914T1 (de) 2009-05-15
US20070015697A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
EP1904056B1 (en) Use of a macrolide to restore corneal sensation
ES2326550T3 (es) Uso de un macrolido para restablecer la sensacion corneal.
Sharif Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision
Sanborn et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device
US20080262415A1 (en) Enhanced wound healing
WO2007038453A2 (en) Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US20070071756A1 (en) Delivery of an agent to ameliorate inflammation
US20080003219A1 (en) Delivery of an ocular agent
US20050025810A1 (en) Treatment of ocular disease
US20080167600A1 (en) Device for delivery of an agent to the eye and other sites
US11045352B2 (en) Methods for treatment of dry eye and other acute or chronic inflammatory processes
PT1755616E (pt) Tratamento de condições patológicas oftálmicas
WO2005082380A1 (en) Heparin for the treatment of ocular pathologies
US20090136514A1 (en) Tetracyclines for Treating Ocular Diseases and Disorders
US20060166956A1 (en) Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
Rizzo et al. Safety results for geographic atrophy associated with age-related macular degeneration using subretinal cord blood platelet-rich plasma
JP2010522774A (ja) 血管新生眼疾患を治療するための方法
CN117279653A (zh) 用于治疗眼部疾病和病症的化合物
US20050261243A1 (en) Antiprostaglandins for the treatment of ocular pathologies
Everaert Evaluation of newly developed HPMC ophthalmic inserts with sustained release properties as a carrier for thermolabile therapeutics
Gote et al. Ocular implants in the clinic and under clinical investigation for ocular disorders
de Zea et al. Dexamethasone intravitreal implant for treatment of persistent macular oedema in Birdshot retinochoroidopathy
Lockwood et al. Novel therapies and future directions

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20081114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120328

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120918